GANX logo

GAIN THERAPEUTICS INC

GANXNASDAQ
🏆 #4231 by market capEarnings Nov 10US Equity
$113.92▼ $5.24 (−4.60%)
Simulated price
🔔
Track GANX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 4.6%
7d▲ 5742.1%
14d▲ 6523.3%
30d▲ 6300.0%
ytd▲ 3432.4%
1y▲ 6246.5%
🏦Market Cap
$77M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
482.8x
Expensive
Otter Score
52
Weak

Trading Snapshot

Day Range
$112.32 – $115.21
52-Week Range
$1.53 – $4.34
Volume
$4.12B
Avg Volume
$5.01B
Shares Outstanding
42.6M
Next Earnings
Oct 28, 2026

Fundamentals Snapshot

Annual Revenue
$160,000
Last Q Revenue
$43,817
P/E Ratio
—
P/S Ratio
482.8x
EPS (TTM)
$-0.51
Dividend Yield
—
Dilution (1yr)
+21.5%

Why Investors Own GANX

  • ✓High-growth profile — revenue up +56.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 36% gross margin and 24% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

GANX logo

GAIN THERAPEUTICS INC

GANX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$19M▼ −8.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$18M▼ −2.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
33.0M▲ +21.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$20M▲ +$10M YoY
StockOtter · stockotter.space

About GAIN THERAPEUTICS INC

Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
52/100

Analyst Price Target

ⓘ
Average Target
$131.56
▲ +15.5% Upside
High Target$149.32
Low Target$118.87
Based on 27 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

GAIN THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift GANX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

GAIN THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.